Sunovion Pharmaceuticals said today that the FDA accepted its new drug application for a sublingual film designed to treat motor fluctuations in people living with Parkinson’s disease.
The U.S. regulatory agency is slated to make a decision regarding Sunovion’s application by January 29.
Get the full story at our sister site, Drug Delivery Business News.